ThermoGenesis Corp announced the introduction of the Res-Q 60 BMC (“Res-Q”) System, an automated cell processing medical device for the concentration of bone marrow-derived stem cells at the point of care.
The Res-Q System processes bone marrow in minutes and delivers a high rate of stem cell recovery. The Res-Q System follows the late 2008 launch of the MXP MarrowXpress (“MXP”) System, a laboratory device also used to collect stem cells from bone marrow.
The Company plans to initially target the orthopedic regenerative medicine market through its orthopedic distribution partner Celling Technologies (“Celling”), a subsidiary of SpineSmith, LLC. Celling serves as a distributor of the MXP System. In a separate press release, ThermoGenesis and Celling announced an expanded collaboration between the two firms. Separately, the Company plans to expand Res-Q’s applications into the cardiovascular and other non-orthopedic regenerative medicine markets.
“We are excited to add a new member to our stem cell processing product family to help us access the growing regenerative medicine market in a meaningful way. We believe our Res-Q System has considerable advantages over competing products and should help surgeons realize the true value of autologous cellular therapy,” said J. Melville Engle, Chief Executive Officer of ThermoGenesis.
“We are delighted to be participating in the launch of the Res-Q System with ThermoGenesis,” said Kevin Dunworth, Chief Executive Officer of SpineSmith, LLC. “The device represents a high level of innovative technology and we look forward to building upon our early success with the MXP,” he added.